Maven Securities’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-11,100
Closed -$3.58M 481
2025
Q3
$3.58M Sell
11,100
-35,200
-76% -$10.9M 0.09% 218
2025
Q2
$18M Buy
+46,300
New +$18.6M 0.43% 48
2025
Q1
Sell
-2,000
Closed -$738K 847
2024
Q4
$738K Buy
2,000
+600
+43% +$251K 0.02% 488
2024
Q3
$728K Sell
1,400
-9,900
-88% -$5.29M 0.01% 575
2024
Q2
$6.12M Buy
+11,300
New +$5.97M 0.14% 156
2024
Q1
Sell
-12,900
Closed -$6.08M 558
2023
Q4
$6.08M Buy
12,900
+600
+5% +$277K 0.13% 121
2023
Q3
$5.36M Buy
12,300
+8,500
+224% +$3.86M 0.06% 176
2023
Q2
$1.69M Buy
3,800
+1,100
+41% +$507K 0.03% 324
2023
Q1
$1.24M Sell
2,700
-2,100
-44% -$999K 0.03% 401
2022
Q4
$2.46M Buy
4,800
+3,800
+380% +$1.93M 0.06% 202
2022
Q3
$454K Sell
1,000
-400
-29% -$191K 0.01% 819
2022
Q2
$676K Hold
1,400
0.02% 484
2022
Q1
$688K Sell
1,400
-2,400
-63% -$1.1M 0.02% 442
2021
Q4
$1.76M Buy
3,800
+2,900
+322% +$1.22M 0.05% 221
2021
Q3
$336K Buy
+900
New +$342K 0.01% 802
2020
Q3
Sell
-1,200
Closed -$316K 638
2020
Q2
$316K Buy
+1,200
New +$320K 0.02% 391

Other funds holding ELV

Maven Securities's ELV Position: Q4 2024 in Review

Maven Securities sold out of Elevance Health (ELV) in Q4 2024, closing a stake of 694 shares — an estimated $290K sold.

Maven Securities first reported a position in ELV in Q2 2020 and held it in 8 quarters. The position peaked at $2.53M in Q3 2022. 1,602 funds tracked by Wall St. Rank hold ELV as of Q4 2024.

  • Maven Securities reported no remaining Elevance Health position as of Q4 2024 after selling out during the quarter.
  • Maven Securities sold 694 Elevance Health shares in Q4 2024, an estimated $290K.
  • Maven Securities first reported a position in Elevance Health in Q2 2020 and held it in 8 quarters.
  • Maven Securities's Elevance Health position peaked at $2.53M in Q3 2022.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q4 2024.

Based on Maven Securities's 13F filing for Q4 2024, filed 14 Feb 2025.